Racura Oncology Unveils Groundbreaking MYC Data at the 2026 Cancer Science Conference

On November 12, 2026, Racura Oncology Limited proudly shared significant preclinical research about their innovative anticancer agent, (E,E)-bisantrene, during the Frontiers in Cancer Science (FCS) 2026 Conference held in Singapore. This data reveals crucial insights into the mechanism by which (E,E)-bisantrene stabilizes the G-quadruplex structure in the MYC gene promoter, substantially inhibiting MYC gene activity.

Unveiling the Mechanism

The research presented underscores (E,E)-bisantrene as the principal active isomer among various molecular forms of bisantrene. Its ability to reinforce the G-quadruplex in MYC's regulatory region leads to decreased MYC gene expression and protein levels. Previous studies indicated that exposure to light diminishes the efficacy of (E,E)-bisantrene, transforming it into less effective isomers. Notably, the preclinical findings illustrated that only 60% of (E,E)-bisantrene remains after 15 minutes of light exposure, with reductions reaching an unmeasurable point after four hours.

In experimental trials utilizing MDA-MB-231 breast cancer cells, pure (E,E)-bisantrene was shown to significantly suppress MYC expression at a half-maximal effective concentration (EC50) of 277 nM, compared to a much higher EC50 of 514-1166 nM for light-exposed isomers. Furthermore, the reduction in cancer cell viability was markedly pronounced, demonstrating that (E,E)-bisantrene effectively reduces cell survival at lower concentrations than its isomeric counterparts.

Expanding the Research Horizon

Racura Oncology's commitment to studying (E,E)-bisantrene's MYC-targeting potential builds upon previous presentations, including its initial data displayed at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The current study's findings reinforce the significance of MYC suppression in cancer progression and offer a promising outlook for Racura's proprietary formulation, RC220, aimed at tackling various oncological challenges.

According to Dr. Daniel Tillett, CEO of Racura Oncology, “These findings confirm that (E,E)-bisantrene stabilizes the G-quadruplex, inhibiting MYC gene expression effectively. Recognizing (E,E)-bisantrene as the active isomer reaffirms our focus on developing RC220.”

Clinical Application and Further Research

RC220 is specifically engineered to target unique DNA and RNA structures associated with oncogenic regulation, which in turn can disrupt the cellular mechanisms driving tumor growth. Given that (E,E)-bisantrene possesses several hydrazone groups capable of isomerizing, understanding its behavior under various conditions is crucial for optimizing therapeutic applications. The efficacy of RC220 makes it a focal point for treating multiple cancer types, including the ongoing EMILI Phase 2b/3 trial addressing acute myeloid leukemia (AML).

This ambitious undertaking demonstrates Racura's dedication to lessening the impact of cancer on a wide range of patients while emphasizing the innovative pathways available through their research. Racura Oncology continues to forge ahead with its collaboration alongside prestigious institutions like Purdue University, focused on fine-tuning the mechanisms associated with (E,E)-bisantrene.

Conclusion

As Racura Oncology navigates the intricate landscape of cancer treatment, the insights presented at the FCS 2026 Conference exemplify the potential of (E,E)-bisantrene as a pivotal player in the fight against cancer. With the ongoing development of RC220, the road ahead promises numerous opportunities for breakthroughs in cancer therapy, underpinning Racura's mission to effectively silence malignant growth pathways and provide hope to patients worldwide.

For more information on Racura Oncology's research and developments, visit www.racuraoncology.com.